** Cryoport's CYRX.O shares jump 23.2% to $7
** CYRX provides supply chain solutions for life sciences companies
** Brokerage UBS upgrades CYRX's rating to "buy" from "neutral"
** Headwinds in CYRX's MVE subsidiary and broader biopharma market weakness have depressed sales, but these challenges are well understood, appear to be stabilizing, and provide an attractive entry point - UBS
** Expect Cryoport to achieve positive free cash flow by 2027, brokerage says
** Scaling cell and gene therapy service offerings provide a credible pathway to low-double-digit+ (~10+) mid-long term sales growth and positive free cash flow - UBS
** As of last close, CYRX had fallen ~27% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。